The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects

Molecular targeted therapy with lenvatinib is commonly offered to advanced hepatocellular carcinoma (HCC) patients, although it is often interrupted by adverse effects which require a reduction in the initial dose. Thus, an alternative lenvatinib-based therapy to compensate for dose reduction is ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Takagi, Hirotetsu, Kaji, Kosuke, Nishimura, Norihisa, Ishida, Koji, Ogawa, Hiroyuki, Takaya, Hiroaki, Kawaratani, Hideto, Moriya, Kei, Namisaki, Tadashi, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001516/
https://www.ncbi.nlm.nih.gov/pubmed/33807929
http://dx.doi.org/10.3390/cells10030575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001516/
https://www.ncbi.nlm.nih.gov/pubmed/33807929
http://dx.doi.org/10.3390/cells10030575

Ejemplares similares